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Abstract
Background: Little is known about the use of psychotropic drugs in older adults receiving domiciliary care. The
first aim was to describe the prevalence and persistency of use of psychotropic drugs in older adults (≥ 70 years)
with and without dementia receiving domiciliary care. Furthermore, the second aim was to explore factors
associated with persistent drug use at two consecutive time-points. Lastly, we aimed to examine if use of
psychotropic drugs changed after admission to a nursing home.
Methods: In total, 1001 community-dwelling older adults receiving domiciliary care at inclusion participated in the
study. Information about psychotropic drug use was collected at baseline, after 18 months and after 36 months. The
participants’ cognitive function, neuropsychiatric symptoms (NPS) and physical health were assessed at the same
assessments. Participants were evaluated for dementia based on all gathered information. Formal level of care
(domiciliary care or in a nursing home) was registered at the follow-up assessments.
Results: Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care was
high. Participants with dementia more often used antipsychotics and antidepressants than participants without
dementia. The majority of the participants using antipsychotic drugs used traditional antipsychotics. Younger
age was associated with higher odds for persistent use of antipsychotics and antidepressants, and lower odds
for persistent use of sedatives. Severity of NPS was associated with persistent use of antidepressants. The
odds for use of antipsychotics and antidepressants were higher in those admitted to a nursing home as
compared to the community-dwelling participants at the last follow-up.
Conclusion: There was a high prevalence and persistency of use of psychotropic drugs. The prevalence of
use of traditional antipsychotics was surprisingly high, which is alarming. Monitoring the effect and adverse
effects of psychotropic drugs is an important part of the treatment, and discontinuation should be considered
when possible due to the odds for severe adverse effects of such drugs in people with dementia.
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Background
Prevalence of psychotropic drug use is high in older
adults (> 70 years) [1, 2]. It is known that the prescrip-
tion rate of psychotropic drugs in western countries in-
creases with higher age [3, 4], and community-dwelling
older adults are prescribed approximately half of all
psychotropic drugs prescribed in Norway [4]. A review
of 67 studies from the USA concluded that one in four
older adults used psychotropic drugs with an abuse or
dependency potential (e.g. benzodiazepines) [3]. The
prevalence of use of anxiolytics and sedatives increase
with age in older adults [5].
In community-dwelling older adults, people with de-
mentia more often use psychotropic drugs than those
without dementia [6, 7]. Neuropsychiatric symptoms
(NPS) following dementia are very common in
community-dwelling older adults receiving domiciliary
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care and in nursing home residents [8, 9]. Chan et al. re-
ported that in a group of community-dwelling older
adults, a clinical diagnosis of dementia, but not the se-
verity of NPS, was associated with the use of psycho-
tropic drugs [10]. Nursing home residents with dementia
more often use antipsychotics than residents without de-
mentia [11–13], and the severity of their NPS is associ-
ated with persistent use of psychotropic drugs [14].
However, non-pharmacological interventions should be the
first-choice treatment of NPS in dementia [15–18], but with
severe NPS psychotropic drug use may be unavoidable.
Antipsychotics are commonly used to treat agitation
in older adults with dementia, for example a recent
study reported the prevalence of antipsychotic use to be
38% [18]. There is little evidence that long term use of
antipsychotics is effective in the management of NPS in
older adults with dementia, but it may have adverse
effects [19], e.g. higher risk of cerebrovascular events
[20, 21], increased risk of falling [22, 23] and a higher
risk of mortality [24, 25]. Atypical antipsychotics are
known to have less extrapyramidal side-effects than
traditional antipsychotics [26], but they are also associ-
ated with a higher risk of hip fractures and a higher risk
of mortality in patients with dementia [27, 28]. Antide-
pressants and benzodiazepines may also cause serious
short- and long-term adverse effects, e.g. increase in falls
[22, 29–31]. While prevalence and persistency of psycho-
tropic drugs in nursing home residents have been studied
and found to be high [9, 14], it remains to be studied
whether persistent use of psychotropic drugs in older
adults receiving domiciliary care is related to having de-
mentia and NPS.
Studies have found that the strongest indicators for
nursing home admission are functional impairment,
cognitive impairment and older age [32–35]. It is
known that older adults in nursing homes frequently
are prescribed psychotropic drugs [9, 14, 36]. There
might be changes in prescription of drugs after admis-
sion to nursing home, especially when it comes to psy-
chotropic drugs [36]. One British longitudinal study has
linked information about psychotropic drug use in
older adults to transition to a nursing home, and found
psychotropic drugs to be prescribed more often after
admission to a nursing home than among those who
continue to live at home [37], but the study did not ad-
just for dementia and other health conditions. To our
knowledge, there are few studies on prescription of psy-
chotropic drugs following admission to long-term nurs-
ing home care [36, 37].
Thus, the first aim of the present study was to describe
the prevalence of psychotropic drug use in persons ≥ 70
years with or without dementia receiving in-home domi-
ciliary care: at the baseline of the study, after 18 months
and after 36 months. The second aim was to assess the
persistency in use of psychotropic drugs, and explore
factors possibly associated with such persistency, i.e. se-
verity of dementia, degree of NPS, physical health and/
or nursing home-admission. The third aim was to ex-
plore whether admission to a nursing home, was associ-
ated with use of these drugs adjusting for severity of
dementia, NPS and physical health.
Methods
Study design
This is a longitudinal study with a 36-month follow-up
period. The baseline data was collected between Au-
gust 2008 and December 2010. Follow-up assessments
were conducted 18 months and 36 months after base-
line-assessment.
Participants
1796 persons (age ≥ 70 years) from 19 municipalities in
the eastern part of Norway were invited to participate in
the study. We chose participants over the age of 70, as it
in Norway, and internationally, has been discussed chan-
ging the limit for being an “old adult” from 65 years or
older, to 70 years or older [38]. The participants had to
be community-dwelling and receiving domiciliary care
from the municipality at inclusion. The amount and
kind of service received were not important. Those eli-
gible for inclusion had to have a next of kin who saw
them at least once every week. Both established recipi-
ents and new recipients of domiciliary care were in-
cluded. New recipients were recruited successively. The
participants were recruited from municipalities of vari-
ous sizes, both rural and urban.
Of the total 1796 invited persons, 795 declined to par-
ticipate in the study. Thus, 1001 persons were included.
Those who declined were more often women and older
than those who participated in the study [8].
Measures
The use of drugs was registered from the participants’
medical records. Drugs were divided into groups accord-
ing to the Anatomical Therapeutic Chemical (ATC) Clas-
sification System. Psychotropic drugs were categorized
into; antipsychotics (N05A except lithium), anxiolytics
(N05B), hypnotics/sedatives (N05C), antidepressants
(N06A), and anti-dementia drugs (N06D). Use of drugs
was dichotomized into yes or no. There were no partici-
pants with missing information about use of drugs.
Dosage of drugs was not available in the present study.
Physical morbidity was evaluated using the General
Medical Health Rating Scale (GMHR), considering the
patients number and severity of medical conditions and
the use of drugs due to these conditions. GMHR is
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scored from 1 to 4, where 1 indicates very poor physical
health and 4 indicates good physical health [39].
The personal activities of daily living (P-ADL) were
measured by the Physical Self-Maintenance Scale
(PSMS), evaluating six different basal needs. Each PSMS
item is scored from 1 to 5, where higher scores indicate
lower P-ADL function [40].
Cognitive function and dementia severity symptoms
were evaluated by the following tools: Mini-Mental State
Examination (MMSE), Clock-Drawing Test (CDT), the
Informant Questionnaire on Cognitive Decline in Elderly
(IQ-CODE) and Clinical Dementia Rating scale (CDR).
MMSE is a standardized test of cognitive function that is
scored from 0 to 30 points. Higher scores indicate good
cognitive function [41]. The Clock Drawing Test is
scored from 0 to 5. A perfect clock is scored 5 [42]. In
the Informant Questionnaire on Cognitive Decline in
Elderly (IQ-CODE), the next of kin assesses the change
in cognitive function during the last decade. The scoring
scale goes from 0 to 5. A score < 3 indicates improve-
ment, > 3 indicates decline and a score of 3 indicates no
change in cognitive function [43]. The CDR includes six
domains; memory, orientation, judgment and problem
solving, community affairs, home functions, and per-
sonal care. An algorithm gives a total score of 0, 0.5, 1, 2
or 3, indicating respectively; no dementia, possible de-
mentia, and mild, moderate and severe dementia [44]. In
the present study, we used CDR sum of boxes
(CDR-SoB), with a point score ranging from 0 to 18,
where a higher score indicates higher severity of demen-
tia [45]. The assessment tools for cognitive function and
severity of dementia have been translated and validated
in Norwegian [46–48].
Neuropsychiatric symptoms (NPS) were evaluated
using the 10-item Neuropsychiatric Inventory (NPI)
[49] in a translated Norwegian version [50]. The fol-
lowing 10 symptoms are covered: delusion, hallucin-
ation, euphoria, agitation/aggression, disinhibition,
irritability/lability, depression/dysphoria, anxiety, ap-
athy/indifference, and aberrant motor behaviour. Each
symptom was rated by the next of kin based on its oc-
currence the previous four weeks.
Dementia was diagnosed independently by two experi-
enced physicians in geriatric psychiatry at all three as-
sessments based on all available information. Dementia
was diagnosed according to the ICD-10 criteria [51]. In
cases of disagreement, consensus was reached after con-
sulting a third clinical expert.
The formal level of care at the follow-up assessments
was registered as location, i.e. community-dwelling receiv-
ing domiciliary care or living in a nursing home. Type of
home support at baseline was registered as nursing care,
domestic help and/or other types of support such as food
delivery, day care centre and safety alarm. Demographic
data including age, gender, municipality of residence and
marital status were registered in the baseline assessment.
Procedure
The process of collecting data material was led by a re-
search nurse that cooperated with the assessors in the
different municipalities. The majority of the assessors
were nurses, social educators and occupational thera-
pists. All the assessors had a two-day course of training
on how to use the assessments scales before the baseline
data collection. A one-day training course was con-
ducted prior to the second and third assessment. The
participants and their next of kin were interviewed sim-
ultaneously by two separate assessors.
Data analysis
Sample characteristics at baseline were presented as
means and standard deviations or as frequencies and
percentages. Participants with dementia and participants
without dementia were compared. Prevalence and per-
sistence of medical drugs by dementia/no dementia and
admission to nursing home/living at home were pre-
sented as percentages. Due to participants belonging to
municipality, data might exhibit hierarchical structure.
Therefore, groups of participants were compared by
linear mixed model (for continuous data) or generalized
linear mixed model (for categorical data) with fixed
effects for dementia status and random intercepts for
municipality, if necessary.
The use of each defined category of psychotropic
drugs given use one or two time-points earlier (Lag 1
and Lag 2, respectively) was assessed by a generalized
linear mixed model with random intercepts for munici-
pality. The dependent variable was use of the given
psychotropic drugs at A2 or A3, while the independent
variable was use of the same category of psychotropic
drugs at baseline. Each model was adjusted for
pre-defined covariates measured at baseline (age, sex,
marital status, CDR, GMHR, PSMS, affective NPS,
psychosis NPS and agitation NPS) and then reduced for
excessive covariates by applying Akaike’s Information
Criteria (AIC) [52], where a lower value indicates a
better model.
To assess factors associated with persistent use of each
category of psychotropic drugs, a generalized linear
mixed model with random effects for patients nested
within municipality was estimated. Dependent variable
was defined as persistent use if the given category of
psychotropic drugs was used at two consecutive
time-points. Adjustment for covariates measured at a
previous time-point was performed. Relative importance
of each covariate in the adjusted models was determined
from standardized regression coefficients. In addition, ef-
fect of location on use of psychotropic drugs at the same
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time-point was assessed by estimating the model with
random effects for patients nested within municipality
and fixed effects for location and interaction between
time and location. The results were adjusted for covari-
ates measured at baseline (age, gender) or at the same
time-point (health measures and marital status). The re-
sults in the adjusted models were presented as odds
ratio (OR) and 95% confidence intervals (CI).
The data was analysed in SPSS version 24 and SAS ver-
sion 9.4. All tests were two-sided. Results with p-values
below 0.05 were considered statistically significant.
Results
Sample characteristics
As shown in Table 1, the mean (SD) age of the total
sample of 1001 participants at baseline was 83.4
(5.7) years, 683 (68.2%) were female and 703 (70.2%)
were single or a widow/widower. Of the participants,
599 (59.8%) were assessed at the second assessment
(A2), and 456 (45.5%) were available for the third as-
sessment (A3) (Fig. 1). At A2 and at A3, 89 (14.9%)
and 114 (25.2%) had been admitted to a nursing
home, respectively.
Prevalence of psychotropic drugs by dementia and place
of living
The prevalence of psychotropic drug use is presented in
Table 2. Sedatives were the most frequently used drugs
at all time-points (varying between 21 and 23%). Anti-
psychotics were the least frequently used types of
psychotropic drug, being 4% at the first (A1) and 7% at
the last time-point (A3). The majority of the participants
using antipsychotics used traditional antipsychotics, and
traditional antipsychotics were also more frequently used
by participants with dementia than by participants with-
out dementia at all time-points. The prevalence of use of
antidepressants was approximately 16% at A1, and 22%
at A3. The prevalence of use of any psychotropic drug
Table 1 Sample characteristics at baseline
Total (N = 1001) Dementia (N = 415) No dementia (N = 586) p-value
Socio-demographics
Age Mean (SD) 83.4 (5.7) 84.5 (5.6) 82.6 (5.6) < 0.001a
Females N (%) 683 (68.2) 273 (65.8) 410 (70.0) 0.171b
Married N (%) 297 (29.7) 131 (31.6) 166 (28.4) 0.250b
Health condition
GMHRd
Good N (%) 155 (15.5) 43 (10.4) 112 (19.1) < 0.001b
Fairly Good N (%) 392 (39.2) 147 (35.5) 245 (41.9)
Poor N (%) 346 (34.6) 166 (40.1) 180 (30.8)
Very Poor N (%) 106 (10.6) 58 (14.0) 48 (8.2)
PSMSe Mean (SD) 9.2 (3.5) 10.9 (4.0) 7.9 (2.6) < 0.001a
NPI Agitation sub-syndromef Mean (SD) 1.6 (4.4) 2.6 (5.7) 0.9 (2.9) < 0.001a,c
NPI Psychosis sub-syndromeg Mean (SD) 0.5 (2.0) 1.1 (2.8) 0.2 (1.1) < 0.001a,c
NPI Affective sub-syndromeh Mean (SD) 2.9 (5.3) 4.8 (6.8) 1.6 (3.3) < 0.001a
No of drugs Mean (SD) 5.3 (2.9) 5.4 (3.0) 5.3 (2.9) 0.699a
Type of domiciliary carei
Nursing care N (%) 670 (67.4) 347 (84.0) 323 (55.6) < 0.001b
Domestic help N (%) 528 (53.1) 210 (50.8) 318 (54.7) 0.229
Other types of support N (%) 599 (59.8) 272 (65.5) 327 (55.8) 0.001b
Agitation sub-syndrome: Agitation/aggression, euphoria, disinhibition, irritability/lability, aberrant motor behavior.
Psychosis sub-syndrome: Delusions, hallucinations
Affective sub-syndrome: Depression/dysphoria, anxiety, apathy/indifference
GMHR General Medical Health Rating, PSMS Physical Self-Maintenance Scale, NPI Neuropsychiatric Inventory
aLinear mixed model
bGeneralized linear mixed model
cNo cluster effect on municipality level
dMissing information in 2 participants
eMissing information in 5 participants
fMissing information in 35 participants
gMissing information in 26 participants
hMissing information in 29 participants
iMissing information in 7 participants
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was high in all three assessments. Antipsychotics,
antidepressants and anti-dementia drugs were more fre-
quently used in those with dementia than in those with-
out dementia at all time-points. Furthermore, we found
the prevalence of use of all types of psychotropic drugs,
except from sedatives at A2, to be higher in those admit-
ted to a nursing home than in those living at home at
A2 and A3 (Table 3).
Persistent use of psychotropic drugs by dementia
The persistent use of psychotropic drugs was high for all
types of psychotropic drugs from A1 to A2 and from A2
to A3, both in participants with and without dementia
(Table 2). Persistent use of any psychotropic drug was
over 80% for the total sample, and it was higher between
A1 and A2 in participants with dementia than in partici-
pants without dementia.
Odds for use of psychotropic drugs at one time-point,
given use of the same type of psychotropic drug at earl-
ier time-points, are presented in Table 4. In general, the
odds for persistent use were highest when compared
with the nearest time-point (Lag 1), but lower when
compared to two time-points earlier (Lag 2). The ad-
justed OR for use of antipsychotics decreased the most,
from 80.5 (28.9; 224.0) to 20.8 (5.8; 75.0), but the odds
for the other drugs were also markedly reduced.
Factors associated with persistent use of psychotropic
drugs at two consecutive time-points
In the adjusted analysis, an increased severity of affective
sub-syndrome of NPI, lower P-ADL function (higher
PSMS), admission to nursing home and younger age
were associated with higher odds for persistent use of
antidepressants (Table 5). Furthermore, younger age was
associated with higher odds for persistent use of antipsy-
chotics, and lower odds for persistent use of sedatives.
Female gender and lower P-ADL function were associ-
ated with higher odds for persistent use of anxiolytics.
Effect of location on use of psychotropic drugs at the
same time-point
The results of effect of time and location on use of psy-
chotropic drugs are presented in Fig. 2. In the adjusted
analysis, the odds for use of antipsychotics and antide-
pressants were higher in those admitted to a nursing
home as compared to the community-dwelling partici-
pants at A3. Please see Additional file 1: Tables S1 and
S2 for further details.
More severe dementia and higher affective sub-syn-
drome scores, lower age and female gender were
associated with higher odds for use of antidepressants
(Additional file 1: Table S1). Higher affective
sub-syndrome and female gender were also associated
with higher odds for use of anxiolytics. Covariates asso-
ciated with higher odds for use of sedatives were lower
P-ADL function and increasing age, whereas good
physical health (higher GMHR) decreased the odds for
use of sedatives.
Discussion
This follow-up study including 1001 community-dwell-
ing older adults (≥ 70 years) receiving domiciliary care at
Fig. 1 Flow chart of participants from baseline (A1) to last follow-up (A3) with a mean (SD) follow-up time at each assessment
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baseline found that participants with dementia had
higher prevalence of any psychotropic drugs than the
participants without dementia. Additionally, the study
revealed that those living in a nursing home at A3 had
higher use of both antipsychotics and antidepressants,
than the community-dwelling participants. Furthermore,
persistent use of different types of psychotropic drugs
was found to be high between the two consecutive as-
sessments, both for participants with and without de-
mentia. The persistent use diminished with longer time
between assessments (Lag 2).
Use of antipsychotics
In the present study, the prevalence of use of antipsy-
chotics was 4% at A1 and 7% at A3. The use of antipsy-
chotics was higher in those with dementia than in those
without dementia. This is in line with previous studies
including community-dwelling participants [53, 54].
Antipsychotics should never be first line treatment in
people with dementia [17, 18], because of the well-known
adverse effects they can cause [17–19]. However, there
might be cases where it is necessary to use antipsychotics
when symptoms are severe and non-pharmacological
treatments are not successful [17, 18]. Unfortunately, we
lack information about non-pharmacological treatments
or efforts that have been tried prior to treatment with an-
tipsychotics. Atypical antipsychotics are preferred in indi-
viduals with dementia rather than traditional
antipsychotics, because of the adverse effects of traditional
antipsychotics [25, 55, 56]. Even so, in the present study
more than 2/3 of all participants using antipsychotics used
traditional antipsychotics, and the prevalence of use of
both traditional and atypical antipsychotics did not change
through our study in those with dementia.
Several participants were admitted to a nursing home
during the follow-up period, and when adjusting for
Table 2 Prevalence and persistence in use of psychotropic drugs
Prevalence n (%)
A1 A2 A3
All D/nD All D/nD All D/nD
(N = 1001) (N = 415/586) (N = 599) (N = 304/295) (N = 453) (N = 227/226)
Psychotropic drug use
Antipsychotics (AP) 36 (3.6) 24/12 (5.8/2.0)** 28 (4.7) 22/6 (7.2/2.0)** 30 (6.6) 26/4 (11.5/1.8)***
Traditional AP 31 (3.1) 19/12 (4.6/2.0)* 23 (3.8) 17/6 (5.6/2.0)* 23 (5.1) 19/4 (8.4/1.8)**
Atypical AP 5 (0.5) 5/0 (1.2/0) 6 (1.0) 6/0 (2.0/0) 8 (1.8) 8/0 (3.5/0)
Antidepressants 155 (15.5) 82/73 (19.8/12.5)** 121 (20.2) 80/41 (26.3/13.9)*** 101 (22.3) 70/31 (30.8/13.7)***
Anxiolytics 86 (8.6) 43/43 (10.4/7.3) 71 (11.9) 48/23 (15.8/7.8)** 53 (11.7) 35/18 (15.4/8.0)*
Sedatives 221 (22.1) 103/118 (24.8/20.1) 128 (21.4) 78/50 (25.7/16.9)* 103 (22.7) 59/44 (26.0/19.5)
Anti-dementia drugs 57 (5.7) 53/4 (12.8/0.7)*** 60 (10.0) 57/3 (18.8/1.0)*** 34 (7.5) 31/3 (13.7/1.3)***
Any PTD 403 (40.3) 208/195 (50.1/33.3)*** 272 (45.4) 178/94 (58.6/31.9)*** 210 (46.4) 132/78 (58.1/34.5)***
Persistence n (%)
A1-A2 A2-A3
All D/nD All D/nD
Psychotropic drug use
Antipsychotics (AP) 17 (63.0)a 12/5 (63.2/62.5) 13 (65.0)a 10/3 (62.5/75.0)
Traditional AP 13 (54.2) 8/5 (50.0/62.5) 11 (64.7) 8/3 (61.5/75.0)
Atypical AP 3 (100) 3/0 (100/0) 1 (25.0) 1/0 (25.0/0)
Antidepressants 83 (82.2) 45/38 (83.3/80.9) 69 (82.1) 41/28 (80.4/84.8)
Anxiolytics 29 (63.0) 17/12 (70.8/54.5) 22 (57.9) 14/8 (53.8/66.7)
Sedatives 77 (66.4) 37/40 (68.5/64.5) 52 (67.5) 27/25 (71.1/64.1)
Anti-dementia drugs 26 (74.3) 24/2 (75.0/66.7) 22 (66.7) 20/2 (64.5/100)
Any PTD 191 (81.3) 106/85 (86.9/75.2)* 142 (83.5) 85/57 (85.9/80.3)
A1: Assessment 1, at baseline
A2: Assessment 2, 18 months after baseline
A3: Assessment 3, 36 months after baseline
D Dementia, nD No dementia, PTD Psychotropic drugs
* p < 0.05; ** p < 0.01; *** p < 0.001; p-values were calculated by generalized linear mixed model adjusting for municipality level if present
aOne participant changed between traditional AP and atypical AP between assessments, which is why the numbers of persistent users of traditional AP plus
persistent users of atypical AP does not equal persistent users of antipsychotics. This is the case for A1-A2 and A2-A3
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differences in health measurements and demographics,
there were elevated odds of using antipsychotics for par-
ticipants that had become nursing home residents at A3.
This is in line with another longitudinal study studying
the transition to nursing home, and studies comparing
people with dementia living in nursing homes and in the
community-dwelling [36, 37, 57], However, these studies
did not adjust for differences in physical health, severity
of dementia and demographics between the groups. We
do not have a firm explanation for the elevated use of
antipsychotics in nursing home residents after adjust-
ment for differences in health and demographics. How-
ever, it might be related to change in place of living and
the stress and strain connected to transition to a nursing
home [58, 59], and to the fact that nursing home resi-
dents have easier access to drug treatment than those
living at home.
We found that a large percentage of participants who
used antipsychotics at one time-point used the same
type of drug at the following time-point. There were no
differences between those with dementia and those with-
out dementia with regard to persistent use of antipsy-
chotics at two following time-points. This is interesting
as antipsychotics, because of the mentioned side-effects,
should only be used for a short period of time in people
with dementia [17, 60]. Also, it is well known that anti-
psychotics may have a limited effect on NPS in dementia
[61, 62]. The persistent use decreased when time be-
tween the two time-points increased to 36months. This
finding corresponds to the results in a longitudinal nurs-
ing home study [14]. We do not have further assessment
time-points to add to our study, but it would have been
interesting to explore the persistency further. We found
no association between severity of psychosis
sub-syndrome and use of antipsychotics at one
time-point, or at two consecutive time-points. If there is
no association between NPS and persistent use of anti-
psychotics, discontinuation should be considered in
older adults with dementia. Other studies have found
that antipsychotics might be discontinued without a sig-
nificant increase in NPS [63]. Even so, there is need for
evaluation and follow-up subsequent a discontinuation
due to the risk of increased NPS after discontinuation
[64].
Use of antidepressants
In the present study, approximately 16% at A1 and 22%
at A3 used antidepressants. In Norway antidepressants
are commonly used in older adults, both in community
dwelling and nursing home residents, and more often in
females [65]. We found that the participants with de-
mentia used antidepressants more frequently than those
without dementia at all time-points and in the adjusted
analysis, we found those with more severe dementia to
be more likely to use antidepressants than those with
less severe dementia. Furthermore, in those with more
severe affective NPS the odds were higher when it came
to the use of antidepressants, which was expected [66,
67]. Depressive symptoms are common in older adults
with dementia [68]. However, the efficacy of antidepres-
sant treatment of depression in people with dementia is
uncertain [69]. In addition, discontinuation of antide-
pressants may reduce NPS and depressive symptoms in
individuals with dementia [69] and are tolerated in most
cases (85%) [70]. However, with discontinuation of anti-
depressants in participants with dementia it is essential
that they are systematically and carefully monitored to
identify those with increasing depressive symptoms [70].
In the adjusted analysis, nursing home residents had
higher use of antidepressants at A3 compared to the
community-dwelling participants at the same
time-point, as reported by others [57]. Entry to nursing
home may as previously mentioned increase the stress
and strain on the residents and thus increase the odds
for use of antidepressants, but in addition the availability
to such treatment when indicated may be better than in
the community-dwelling.
Not only the prevalence, but also the persistent use of
antidepressants was high, both in those with and without
dementia. In line with the results from a nursing home
study [14], the present study found that higher severity
of affective symptoms increased the odds for persistent
use of antidepressants. Furthermore, we found that
lower P-ADL function increased the odds for persistent
use of antidepressants. We do not have a firm explan-
ation, but it might be that those with lower P-ADL func-
tion, due to the situation of being more dependent on
Table 3 Prevalence in use of psychotropic drugs according to
nursing home admission
A2 A3
NHA/no NHA NHA/no NHA
(N = 89/510) (N = 114/339)
Psychotropic drug use
Antipsychotics (AP) 11.2 / 3.5** 18.4 / 2.7***
Traditional AP 7.9 / 3.1* 12.3 / 2.7***
Atypical AP 4.5 / 0.4** 7.0 / 0
Antidepressants 33.7 / 17.8** 43.0 / 15.3***
Anxiolytics 20.2 / 10.4* 21.1 / 8.6**
Sedatives 25.8 / 20.6 32.5 / 19.5**
Anti-dementia drugs 23.6 / 7.6*** 20.2 / 3.2***
Any PTD 67.4 / 41.6*** 73.7 / 37.2***
A2: Assessment 2, 18 months after baseline
A3: Assessment 3, 36 months after baseline
NHA Nursing home admission, no NHA Living at home, PTD
Psychotropic drugs
* p < 0.05; ** p < 0.01; *** p < 0.001; p-values were calculated by generalized
linear mixed model adjusting for municipality level if present
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others, have symptoms of depression not covered by the
NPI.
Use of sedatives, anxiolytics and anti-dementia drugs
The most prevalent type of psychotropic drugs used in
this sample were sedatives, with a prevalence of approxi-
mately 21–23% at the assessments. The prevalence of
use of sedatives was lower in a population-based study
of assumingly healthier community-dwelling older adults
than the prevalence found in our study [71], but these
samples are difficult to compare. For example, in the
present study, use of sedatives at one time-point was as-
sociated with lower P-ADL function, poor physical
health (low GMHR) and higher age, as found in other
studies [72, 73].
The prevalence of anxiolytics remained quite stable
at all three assessments (approximately 9–12%). The
use of anxiolytics at one time-point was found to be
associated with female gender and higher affective
sub-syndrome of NPI at the same time-point, but
persistent use of anxiolytics was not associated with
affective sub-syndrome at the first time-point. Thus,
this may indicate that change in affective
sub-syndrome of NPI have importance for discontinu-
ation of anxiolytics in the present study.
The prevalence of anti-dementia drugs was found to be
low. However, some participants without a dementia diag-
nosis were using anti-dementia drugs. The explanation
may be that the general practitioner usually prescribing
the drugs, may prescribe the drugs because of suspicion of
dementia [74]. The prevalence of anti-dementia drug
use was in the descriptive analysis higher in nursing
home residents, but we did not explore the use of
anti-dementia drugs further, thus the findings may be
due to the fact that also the prevalence of dementia
was higher in nursing homes.
Strengths and limitations
This study has significant strengths. Firstly, all nurses
participating in the data collection were trained in a
2-day educational course prior to the first data collection
and further one-day repetition before the second and
last assessment to ensure adequate knowledge prior to
the data collection. Secondly, a large sample size made it
Table 4 OR for use of each category of psychotropic drugs at one time-point given use one or two time-points earlier, respectively,
lag 1 and lag 2, covariates were measured at baseline
Variable Number of users Unadjusted Adjustedb
Baseline A2 OR (95% CI) p-value OR (95% CI) p-valueo
Lag 1 (N=565a)
Antipsychoticsc 26 27 76.8 (28.5; 207.2) < 0.001 80.5 (28.9; 224.0) < 0.001
Antidepressantsd 97 118 53.3 (28.6; 90.1) < 0.001 47.3 (25.1; 89.1) < 0.001p
Anxiolyticse 44 67 25.9 (12.0; 55.5) < 0.001 23.6 (10.7; 52.1) < 0.001
Sedativesf 109 118 17.3 (10.5; 28.6) < 0.001 18.2 (10.9; 30.4) < 0.001
Lag 2 (N=432a)
Baseline A3
Antipsychoticsi 17 29 24.2 (7.1; 83.1) < 0.001 20.8 (5.8; 75.0) < 0.001
Antidepressantsj 66 97 29.8 (15.0; 59.2) < 0.001 28.1 (13.8; 57.4) < 0.001p
Anxiolyticsk 32 50 10.4 (4.5; 23.9) < 0.001 11.4 (4.5; 28.7) < 0.001
Sedativesl 74 98 6.6 (3.8; 11.3) < 0.001 6.6 (3.8; 11.4) < 0.001
Lag 1: Two consecutive assessment time points (baseline and A2)
Lag 2: One time point between selected time points (baseline and A3)
a Cases with at least one missing on covariates were excluded
bFollowing adjustment variables considered: Age, gender, marital status, CDR-SoB, GMHR, PSMS, NPI Affective sub-syndrome, NPI Psychosis sub-syndrome, NPI
Agitation sub-syndrome all measured at A1 (baseline); Nursing home admission was not included as adjustment variable (no baseline values available); both
models reduced by AIC
cAdjusted for Gender
dAdjusted for CDR-SoB and NPI Affective sub-syndrome
eAdjusted for PSMS and NPI Affective sub-syndrome
fAdjusted for NPI Affective sub-syndrome and NPI Agitation sub-syndrome
gAdjusted for PSMS
hAdjusted for CDR-SoB and NPI Psychosis sub-syndrome
iAdjusted for Gender and PSMS
jAdjusted for CDR-SoB, NPI Affective sub-syndrome and NPI Psychosis sub-syndrome
kAdjusted for Marital status, GMHR and NPI Affective sub-syndrome
lAdjusted for Age and CDR-SoB
mAdjusted for Marital status and CDR-SoB
nAdjusted for Gender, Age, Marital status and CDR-SoB
op-values were calculated by generalized linear mixed model adjusting for municipality level if present
p no cluster effect at municipality level present
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possible to adjust for many potential covariates. Lastly, it
is a strength that the participants included in this study
came from municipalities covering a larger part of the
country and municipalities with both rural and urban
areas. However, because inclusion was not based on a
random selection from all parts of Norway, we cannot
guarantee that the sample is representative for all older
adults in Norway receiving domiciliary care.
The study has some limitations of importance.
Firstly, participants were not randomly selected, and
several refused to participate at baseline. In addition,
our study included an expected frailer part of the
community-dwelling older adults, as opposed to those
without any kind of domiciliary care needs. Another
inclusion criterion was that the participants had to
have a next of kin that saw them at least once every
week. Thus, cautions with regard generalizations of
study results should be taken. Secondly, we have infor-
mation about use of psychotropic drugs only from the
medical record. It was not cross-checked with the
Norwegian Prescription Database [65], the patient or
the next of kin whether the drug still was prescribed
and taken. Furthermore, we lack information about
length of use and attempts of discontinuation between
assessment points. Thirdly, at baseline some of the
participants were already regular users of domiciliary
care while others were recruited when first enrolled in
the domiciliary care services. Lastly, the results of
Table 5 OR for use of each category of psychotropic drugs at one time-point given use of the same drug at the previous time
point with covariates measured at the same previous time-point
Variable Antipsychotics (N = 954) Antidepressants (N = 954)
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Assessed at previous time-point
CDR-SoB 1.14 (1.04; 1.24) 0.005 1.04 (0.91; 1.19) 0.5824 1.13 (1.07; 1.19) < 0.001 1.04 (0.96; 1.13) 0.3465
GMHR (Good/fairly good) 0.56 (0.26; 1.22) 0.145 1.08 (0.43; 2.73) 0.8669 0.91 (0.59; 1.40) 0.668 1.37 (0.84; 2.23) 0.2146
PSMS 1.17 (1.07; 1.28) 0.001 1.13 (0.99; 1.29) 0.0572 1.13 (1.07; 1.20) < 0.001 1.10 (1.01; 1.19) 0.0253
NPI Agitation sub-syndrome 1.07 (1.00; 1.14) 0.049 1.03 (0.94; 1.13) 0.5575 1.05 (1.00; 1.10) 0.037 0.97 (0.91; 1.02) 0.2488
NPI Psychosis sub-syndrome 1.10 (0.97; 1.25) 0.148 0.98 (0.79; 1.22) 0.86710 1.12 (1.02; 1.23) 0.018 1.04 (0.93; 1.17) 0.48210
NPI Affective sub-syndrome 1.03 (0.96; 1.09) 0.410 1.01 (0.92; 1.11) 0.8338 1.09 (1.05; 1.13) < 0.001 1.08 (1.03; 1.13) 0.0012
Married 1.46 (0.64; 3.30) 0.365 0.84 (0.30; 2.39) 0.7487 0.69 (0.40; 1.20) 0.186 0.71 (0.38; 1.33) 0.2877
Entry to NH 3.57 (1.11; 11.50) 0.033 1.67 (0.40; 7.01) 0.4886 3.54 (1.64; 7.68) 0.001 2.52 (1.02; 6.26) 0.0474
Assessed at baseline
Age 0.92 (0.86; 0.98) 0.016 0.91 (0.84; 0.99) 0.0341 0.95 (0.91; 0.99) 0.021 0.93 (0.89; 0.97) 0.0011
Males 2.42 (1.12; 5.22) 0.025 2.10 (0.80; 5.53) 0.1333 0.68 (0.39; 1.16) 0.153 0.74 (0.40; 1.35) 0.3199
Anxiolytics (N = 954) Sedatives (N = 954)
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Assessed at previous time-point
CDR-SoB 1.13 (1.06; 1.21) < 0.001 1.05 (0.94; 1.17) 0.3774 1.05 (0.99; 1.11) 0.074 0.99 (0.92; 1.08) 0.8499
GMHR (Good/fairly good) 0.80 (0.43; 1.51) 0.493 1.05 (0.51; 2.13) 0.9019 0.64 (0.41; 0.98) 0.039 0.70 (0.44; 1.12) 0.1373
PSMS 1.15 (1.06; 1.24) < 0.001 1.13 (1.01; 1.26) 0.0312 1.09 (1.03; 1.16) 0.002 1.08 (0.99; 1.17) 0.0562
NPI Agitation sub-syndrome 1.05 (0.99; 1.11) 0.089 0.98 (0.91; 1.06) 0.6658 1.02 (0.97; 1.07) 0.474 1.01 (0.95; 1.07) 0.81310
NPI Psychosis sub-syndrome 1.13 (1.01; 1.27) 0.029 1.06 (0.92; 1.22) 0.4226 1.01 (0.91; 1.12) 0.892 0.96 (0.85; 1.10) 0.5767
NPI Affective sub-syndrome 1.07 (1.02; 1.13) 0.003 1.04 (0.98; 1.10) 0.1673 1.03 (0.99; 1.07) 0.123 1.02 (0.98; 1.07) 0.3675
Married 0.91 (0.43; 1.93) 0.801 1.52 (0.65; 3.59) 0.3375 0.77 (0.45; 1.32) 0.336 0.77 (0.43; 1.40) 0.3964
Entry to NH 1.63 (0.50; 5.36) 0.420 0.67 (0.17; 2.60) 0.5617 1.29 (0.51; 3.23) 0.589 0.77 (0.28; 2.13) 0.6088
Assessed at baseline
Age 1.02 (0.96; 1.09) 0.438 1.00 (0.94; 1.07) 0.97810 1.07 (1.02; 1.12) 0.003 1.07 (1.02; 1.12) 0.0051
Males 0.23 (0.08; 0.69) 0.009 0.18 (0.05; 0.61) 0.0061 1.00 (0.61; 1.66) 0.988 1.17 (0.67; 2.06) 0.5856
CDR-SoB Clinical Dementia Rating – Sum of Boxes
GMHR General Medical Health Rating, PSMS Physical Self-Maintenance Scale, NPI Neuropsychiatric Inventory, NH Nursing Home
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persistent use of psychotropic drugs, particularly anti-
psychotics, might suffer from low power, especially in
the adjusted models.
Clinical implications
It’s been known that the use of psychotropic drugs, espe-
cially antipsychotic drugs, among nursing home resi-
dents has been extensive. In Norway, as well as
internationally, one has been working towards prescrib-
ing less psychotropic drugs in nursing homes. We have
not had the same focus on the use of psychotropic drugs
among older adults living at home, with and without de-
mentia. Our study may contribute to broaden the focus
to also include older adults, living at home with a need
of domiciliary care. In such cases the GP has the respon-
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Fig. 2 Interaction between time and location for use of Antipsychotics, Antidepressants, Anxiolytics and Sedatives
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communication with the provider of domiciliary care so
that e.g. follow-up of possible side-effects from discon-
tinuation can be observed and registered. Less prescrip-
tion of psychotropic drugs, may also introduce better
treatment alternatives for NPS in older adults, e.g. milieu
therapy.
Conclusion
The prevalence and persistency of psychotropic drugs in
older adults receiving domiciliary care at inclusion was
high. The use of antipsychotics was higher in those with
dementia than in those without dementia at all assess-
ment time-points, and a high proportion of those using
antipsychotics used traditional antipsychotics. Nursing
home admission during follow-up was associated with
increased odds for use of both antipsychotics and anti-
depressants at the last follow-up. Monitoring effects and
adverse effects of psychotropic drugs is an important
part of the treatment, and discontinuation of drugs
should be considered regularly.
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